

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 November 2003 (06.11.2003)

PCT

(10) International Publication Number
WO 03/090807 A1

(51) International Patent Classification⁷: **A61L 31/10**, 31/16

(21) International Application Number: PCT/US03/12831

(22) International Filing Date: 23 April 2003 (23.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/375,182 24 April 2002 (24.04.2002) US

(71) Applicant (for all designated States except US): **POLY-MED, INC.** [US/US]; 6309 Highway 187, Anderson, SC 29625 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **SHALABY, Shalaby, W.** [US/US]; 6309 Highway 187, Anderson, SC 29625 (US).

(74) Agent: **GREGORY, Leigh, P.**; P.O Box 168, Clemson, SC 29633-0168 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MULTIFACETED ENDOVASCULAR STENT COATING FOR PREVENTING RESTENOSIS

(57) Abstract: This invention deals with a carboxyl-bearing, amphiphilic, solid copolyester stent coating composition for multifaceted prevention of vascular restenosis through a plurality of physicochemical modes. The composition includes one or more bioactive compounds and a copolymerization product of polyalkylene glycol, end-grafted with one or more cyclic monomer and treated further to introduce carboxyl-bearing end- or side- groups. The invention also deals with bioactive agents in an ionically conjugated form. The present coating may be applied to a metallic or an absorbable polymeric stent for use in preventing vascular restenosis.

WO 03/090807 A1

MULTIFACETED ENDOVASCULAR STENT COATING FOR PREVENTING RESTENOSIS

FIELD OF THE INVENTION

5 This invention relates to biomedical applications of an amphiphilic, absorbable copolyester stent coating, which includes a bioactive agent to provide a multifaceted composition for preventing vascular restenosis through the simultaneous display of more than two of the key properties associated with rendering metallic and polymeric endovascular stents effective in preventing or minimizing restenosis.

BACKGROUND OF THE INVENTION

Cardiovascular and luminal stents are highly effective in the treatment of heart disease and other vascular conditions by the dilation and retention of constricted vessels or bodily conduits. However, their insertion may induce undesirable bodily reactions such as inflammation, infections, thrombosis or blood clots, restenosis, and proliferation of cell growth that occludes the passageway and may incur the need for additional surgery. Pharmaceutical drugs and compounds may assist in preventing these conditions, although they may be required in large oral or intravenous doses with stringent intake or injection timetables to increase their efficacy.

20 Pharmaceutical compounds may be coated directly on the stent to provide a preferable point-of-use drug delivery system, but these coatings must be bioengineered to control the release of sometimes highly potent and potentially toxic drugs. Timed-release attributes of a coating must be incorporated to avoid clinically unacceptable releases of toxic levels of potent drugs. Biocompatible, biodegradable polymers for various biomedical applications such as those used in sutures and tissue engineering have been described in "Functionalized Polyester Graft Copolymers," Hrkach, et al., U.S. Patent No. 5,654,381, issued Aug. 5, 1997. Drug-polymers based on polylactide and drug mixtures in particle or pellet form to provide timed-release delivery are described in "Polylactide-Drug Mixtures," Boswell, et al., U.S. Patent No. 3,773,919, issued Nov. 20, 1973, or in a spray form as described in "Polylactide-Drug Mixtures for Topical Application," Scribner, et al., U.S. Patent No. 3,755,558, issued Aug. 28, 1973.

These developments in pharmaceutical coatings, however, have limited control over the delivery of the drug and versatility in the types of drugs to be delivered and their pharmacodynamics. The delivery of the drug may be too fast, ineffective and possibly toxic, or too slow and ineffective. The drug coating may not stick or adhere. The drug polymer coatings should coat the stent framework without cracking, peeling or delaminating, particularly when the stent is expanded during installation. The coating should not fall off, crack, fracture, crystallize or melt during processing, sterilizing, or installing. In some cases, a rapid delivery of a drug may be needed immediately following surgery, followed by a steady delivery of the drug at a lesser rate over an extended period of time. Because there is need for the *in vivo* delivery of more than one drug, delivery of one or multiple drug types from a deployed, coated stent with variable elution rates is desirable. One drug type in a polymer coating may elute faster than another drug type in the same polymer, thus methods of modulating a drug without impacting its bioactive moiety are desirable.

In spite of the broad coverage of the prior art on the use endovascular stents for the prevention of restenosis entailing many types of stent polymeric barrier coatings and bioactive agents for inhibiting restenosis, integrating the role of both components into a physico-pharmacologically unique entity to maximize their efficacy as a physical barrier and pharmacologically active agent was left unaddressed. This and the availability of new forms of bioactive agents with more than one pharmacological effect provided an incentive to explore the concept of multifaceted coating composition subject of this invention.

SUMMARY OF THE INVENTION

Accordingly, the objective of this invention is to design a multifaceted coating composition, wherein the bioactive agent has more than one pharmacological attribute for preventing restenosis and also interacts with a functional polymeric barrier to modulate its bioavailability.

This and other goals are achieved by providing an absorbable, amphiphilic, solid copolyester stent coating composition for multifaceted prevention of vascular restenosis through a plurality of physicopharmacological modes, which includes at least one

bioactive compound and a segmented/block copolymer having a central polyoxyalkylene segment and at least one terminal segment derived from at least one cyclic monomer, the copolymer having at least one carboxyl group per chain. Preferably, the polyoxyalkylene segment is polyoxyethylene and the chain has at least one carboxyl side group introduced by free-radically achieved maleation. Alternatively, the chain may include at least one carboxyl end group introduced by acylation of the at least one terminal segment with glutaric anhydride. In a preferred embodiment the at least one bioactive compound is a combination of two bioactive compounds such as an antiangiogenic compound and a non-steroidal anti-inflammatory drug, an antineoplastic agent and a non-steroidal anti-inflammatory drug, an antineoplastic agent and an anti-platelet aggregation drug, an antiangiogenic agent and anti-platelet aggregation drug, paclitaxel and a non-steroidal anti-inflammatory drug, or lanreotide and trapidil. For the latter embodiment it is preferred that the lanreotide is at least partially conjugated ionically with the segmented/block copolymer. In another embodiment the at least one bioactive compound is an ionic conjugate of a basic antiangiogenic peptide and an acidic non-steroidal anti-inflammatory drug. For such embodiment the acidic non-steroidal anti-inflammatory drug may be naproxen. The basic antiangiogenic peptide may be an LHRH analog or a somatostatin analog. In another embodiment the at least one bioactive compound is a combination of an antiangiogenic peptide, such as lanreotide, and an anti-platelet aggregation agent, such as trapidil, and the two are ionically conjugated with the segmented/block copolymer.

The present invention is also directed to a metallic endovascular stent coated with the present inventive absorbable stent coating. Further, the present invention is directed to an absorbable endovascular stent coated with the present inventive absorbable stent coating.

DESCRIPTION OF PREFERRED EMBODIMENTS

The primary objective of the present invention is to provide a coated, endovascular, metallic or polymeric stent comprising one or more bioactive agent that inhibits or minimizes the incidence of vascular restenosis. A preferred aspect of this invention deals with a metallic stent coated with a compliant, metal-adhering, absorbable copolyester that

maximizes the mechanical biocompatibility of the metallic stent with the surrounding vascular tissues. Another preferred aspect of this invention deals with an absorbable amphiphilic copolyester coating on a metallic or polymeric endovascular stent with propensity for hydrophilic as well as hydrophobic bioactive agents. A specific aspect of this invention deals with a coating made by end-grafting a polyalkylene glycol and preferably polyethylene glycol with one or more of the following monomer, glycolide, trimethylene carbonate, lactide, ϵ -caprolactone, p-dioxanone, and 1,5-dioxepan-2-one that is further reacted with maleic anhydride in the presence of a free radical initiator to introduce anhydride side groups that can be converted to carboxylic groups. Another preferred aspect of this invention deals with a carboxyl-bearing, absorbable, amphiphilic copolyester capable of adhering to the surface of a metallic stent as well as ionic conjugation with basic bioactive agents. Another aspect of this invention deals with an absorbable, amphiphilic, carboxyl-bearing copolyester coating capable of (1) ionic conjugation with basic bioactive agents; and (2) adhering to an absorbable stent through chain interdiffusion at the stent/coating interface and/or acid-base interaction. Another preferred aspect of this invention deals with a coating comprising one or more bioactive agent that displays antiangiogenic, anti-inflammatory, and anti-neoplastic effects. A specific aspect of this invention describes the bioactive agent as a cyclic octapeptide. A more specific aspect of the invention describes the bioactive agent as cyclic octapeptide somatostatin analog such as those cited by Barrie et al., [*J. Surg. Res.*, 55, 446 (1993)] as the antiangiogenic peptide type, lanreotide. Another specific aspect of this invention describes the bioactive agent of a lutenizing human releasing hormone (LHRH) analog. A preferred aspect of this invention describes a basic somatostatin or LHRH analog as being present in part or fully as an ionic conjugate of a carboxyl-bearing anti-inflammatory drug such as naproxen. Another aspect of this invention deals with (1) a combination of an antineoplastic agent, such as paclitaxel or curcumin, and anti-inflammatory drug, such as naproxen; and (2) an antineoplastic agent, such as paclitaxel or curcumin, and an anti-platelet aggregation drug, such as trapidil. Another aspect of this invention deals with a mixture of bioactive agents comprising anti-angiogenic peptide such as one of the somatostatin analogs described above and a non-steroidal, anti-inflammatory drug

(NSAID) such as naproxen. Another aspect of this invention deals with a mixture of bioactive agents comprising one of the somatostatin analogs described above and a second agent that is capable of mediating inflammation as well as inhibiting platelet aggregation such as trapidil. A specific aspect of this invention deals with a carboxyl-bearing
5 amphiphilic copolyester stent coating, which is at least partially conjugated with a basic antiangiogenic peptide, such as lanreotide, and trapidil.

Another aspect of this invention deals with a non-absorbable, compliant, metal-adhering coating on an expandable metallic stent such as (1) butyl-methacrylate/methacrylic acid copolymer; and (2) vinyl-acetate butyl-methacrylate
10 methacrylic acid terpolymer. A preferred aspect of this invention deals with one of the aforementioned types of non-absorbable coatings containing one or more of the bioactive agents described above in connection with the absorbable coating. A specific aspect of the non-absorbable coating deals with its use to bind at least part of a basic peptide, such as one of those noted above in the form of an ionic conjugate to control the release of such
15 peptide.

Another aspect of this invention deals with the ionic conjugation of the carboxyl-bearing coating polymer with the basic peptide, which can be achieved by mixing an aqueous solution of an acetate salt of the peptide with a solution of the carboxyl-bearing polymer in a water-soluble solvent such as acetonitrile followed by separation of the
20 precipitated polymer/peptide ionic conjugate. Alternatively, the peptide solution is allowed to react with an alkali metal salt of the carboxyl-bearing polymer to yield a precipitate of the polymer-peptide ionic conjugate.

Another aspect of this invention deals with a method of applying a solution of the coating on to a metallic or absorbable polymeric stent using any of the conventional
25 methods, such as spraying, dipping, and ultrasonic atomization of a polymer solution comprising the bioactive agent or agents, followed by solvent removal by drying.

Additional illustrations of the present invention are given in the Examples discussed below:

EXAMPLE 1:**Preparation of an Absorbable, Amphiphilic Copolyesters with Carboxy-bearing Side-groups: General Method**

In the first step, a predried polyethylene glycol is end-grafted with one or more
5 cyclic monomer (e.g., ϵ -caprolactone, trimethylene carbonate, L-lactide, glycolide, 1,5-dioxepan, and p-dioxanone) by a ring-opening mechanism, using a catalytic amount of stannous octoate at 150-60°C for the proper period of time until practically a complete conversion of the monomer(s) is achieved (as determined by GPC). The resulting
10 amphiphilic polymer is characterized for identity (IR and NMR), thermal properties (DSC), and molecular weight (GPC). In the second step, a solution of the amphiphilic polymer in a suitable solvent (e.g., toluene, dioxane) is reacted with maleic anhydride in the presence of a free-radical initiator (e.g., benzoyl peroxide, azo-bis-butyronitrile) at a suitable temperature (65-80°C) for an appropriate period of time. The third step entails the
15 treatment of the maleated product from Step 1 with water at 50°C for 8-16 hours or until complete conversion of the anhydride side-groups to carboxylic groups (as determined by IR). The carboxyl-bearing polymer is then separated in a series of steps consisting of solvent evaporation under reduced pressure, rinsing with water, and centrifugation. The resulting product is characterized for identity (IR, NMR), thermal properties (DSC), molecular weight (GPC), and carboxyl content (acidimetry).

20

EXAMPLE 2:**Preparation of Absorbable Amphiphilic Copolyester Based on Eng-grafted Polyethylen Glycol (PEG) and Carboxyl-bearing Side-groups**

Using the general procedure of Example 1, PEG-5000, PEG 8000, and PEG-10,000
are converted to three different amphiphilic copolyesters (AMP-S1 to AMP-S3) as outlined
25 in Table I. Hydrolysis of the anhydride group is conducted as in Example 1. The polymers are characterized for their identity, molecular weight, and thermal properties as discussed in Example 1.

Table I.
Preparation of AMP-S1 to AMP-S3

	Copolymer Number		
	AMP-S1	AMP-S2	AMP-S3
• PEG Used, Average Molecular Weight, Da	4600	8000	10,000
• End-grafting polymerization charge ^a			
- PEG, moles	0.02	0.016	0.001
- ϵ -Caprolactone, moles	1.8	1.8	1.8
- L-Lactide, moles	0.2	0.2	0.2
- Stannous octoate, mmole	0.2	0.2	0.2
• Maleation Reaction ^b			
- Maleic anhydride, moles	0.06	0.048	0.003
-Azo-catalyst, g	1.5	1.5	1.5

^aAll reactions are conducted at 150°C for 16-20 hours, or until complete monomer conversion. ^bAll reactions are conducted at 65°C for 2-4 hours or until completion (as determined by IR).

EXAMPLE 3:
Preparation of Carboxyl-terminated, Absorbable Amphiphilic Copolyester - General Method

This entails two steps. In the first step, a predried polyethylene glycol is end-grafted with one or more cyclic monomer (e.g., ϵ -caprolactone, trimethylene carbonate, L-lactide, glycolide, 1,5-dioxepan, and p-dioxanone) by a ring-opening mechanism, using a catalytic amount of stannous octoate at 150-60°C for the proper period of time until practically a complete conversion of the monomer(s) is achieved (as determined by GPC). The resulting amphiphilic polymer is characterized for identity (IR and NMR), thermal properties (DSC), and molecular weight (GPC). The second step entails the reaction of the end-grafted copolymer from Step 1 with a stoichiometric amount of glutaric anhydride at 140 to 160°C for 3-4 hours or until end-group acylation is practically completed. The resulting polymer is characterized for identity (IR, NMR), thermal properties (DSC), molecular weight (GPC), and carboxylic content (acidimetry).

EXAMPLE 4:**Preparation of Carboxyl-terminated Absorbable Copolyester of Different PEGs**

Using the general method of Example 3, PEG-2000, PEG-3000 and PEG-5000 are converted into three amphiphilic copolyesters (AMP-T1 to AMP-T3) as outlined in Table

5 II. The carboxyl-terminated copolyesters are characterized as described in Example 3.

Table II.
Preparation of AMP-T1 to AMP-T3

	Copolymer Number		
	AMP-T1	AMP-T2	AMP-T3
• PEG Used, Average Molecular Weight, Da	2000	3400	4600
- End-grafting polymerization charge ^a			
- PEG, moles	0.05	0.025	0.02
- Caprolactone, moles	1.8	1.8	1.8
- L-Lactide, moles	0.2	0.2	0.2
- Stannous octoate, mmole	0.2	0.2	0.2
• Maleation Reaction ^b			
- Maleic anhydride, moles	0.1	0.05	0.04

^aAll reactions are conducted at 150°C for 16-20 hours or until complete monomer conversion. ^bAll reactions are conducted at 65°C for 2-4 hours or until complete

10 consumption of the anhydride is realized (as determined by IR).

EXAMPLE 5:**Preparation of Bioactive AMP-S1 Formulation with Lanreotide and Trapidil Hydrochloride and Stent Coating Therewith**

This entails two steps. In the first step, AMP-S12 (1 g) from Example 2 is
 15 dissolved in acetonitrile (10 mL) and neutralized with aqueous sodium bicarbonate. To this is added, while stirring, a solution of lanreotide acetate (0.1 g) in water (0.5 mL) and mixing is continued for 1 hour at 25°C to complete the formation of the AMP-S—lanreotide ionic conjugate. The latter was lyophilized to rid of the liquid components. The solid ionic conjugate is then redissolved in methylene chloride (10 mL) and a finely
 20 divided rapidil hydrochloride (0.1 g) is added while stirring. The solution of the bioactive

formulation is filter-sterilized. The sterilized solution can then be applied to the metallic stent (or absorbable stent using non-solvent for stent upon preparing the sterile solution) by standard techniques (ultrasonic spraying, dipping). The coated stent is dried in a laminar flow hood prior to packaging.

5

EXAMPLE 6:**Preparation of a Bioactive AMP-T1 with Lanreotide and Trapidil and Stent Coating Therewith**

This is pursued under similar conditions to those described in Example 5 with the exception of substituting AMP-T1 for AMP-S1.

10

EXAMPLE 7:**Preparation of Bioactive AMP-S1 Ionically Conjugated with Lanreotide and Trapidil**

AMP-S1 (1 g) from Example 2 is dissolved in acetonitrile (10 mL) and neutralized with aqueous sodium bicarbonate. To this is added, while stirring, a solution of lanreotide acetate (0.08 g) in water (0.5 mL) followed by a solution of trapidil hydrochloride (0.002 g) in water (0.2 mL). Mixing is continued for 1 hour at 25°C to complete the formulation of AMP-S1 ionic conjugate with lanreotide and trapidil. The reaction product is lyophilized to yield the solid conjugate.

15

EXAMPLE 8:**Preparation of Ionic Conjugates of Lanreotide and Naproxen**

20

A solution of lanreotide acetate (1 mmole, based on the active free base) in water (2.5 mL) is mixed with naproxen in the free acid form (1 mmole). The mixture of the two compounds is stirred at 25°C under a nitrogen atmosphere until a clear solution is obtained. The latter is then lyophilized to produce a ready-to-use solid conjugate.

25

Although the present invention has been described in connection with the preferred embodiments, it is to be understood that modifications and variations may be utilized without departing from the principles and scope of the invention, as those skilled in the art will readily understand. Accordingly, such modifications may be practiced within the scope of the following claims. Moreover, Applicants hereby disclose all sub-ranges of all ranges disclosed herein. These sub-ranges are also useful in carrying out the present invention.

30

WHAT IS CLAIMED:

1. An absorbable, amphiphilic, solid copolyester stent coating composition for multifaceted prevention of vascular restenosis through a plurality of
5 physicopharmacological modes comprising at least one bioactive compound and a segmented/block copolymer comprising a central polyoxyalkylene segment and at least one terminal segment derived from at least one cyclic monomer, the copolymer further comprising at least one carboxyl group per chain.
- 10 2. An absorbable stent coating as set forth in claim 1 wherein the polyoxyalkylene segment comprises polyoxyethylene and wherein the chain comprises at least one carboxyl side group introduced by free-radically achieved maleation.
- 15 3. An absorbable stent coating as set forth in claim 1 wherein the polyoxyalkylene segment comprises polyoxyethylene and wherein the chain comprises at least one carboxyl end group introduced by acylation of the at least one terminal segment with glutaric anhydride.
- 20 4. An absorbable stent coating as set forth in claim 1 wherein the at least one bioactive compound comprises an antiangiogenic compound and a non-steroidal anti-inflammatory drug.
- 25 5. An absorbable stent coating as set forth in claim 1 wherein the at least one bioactive compound comprises an antineoplastic agent and a non-steroidal anti-inflammatory drug.
6. An absorbable stent coating as set forth in claim 1 wherein the at least one bioactive compound comprises an antineoplastic agent and an anti-platelet aggregation drug.

30

7. An absorbable stent coating as set forth in claim 1 wherein the at least one bioactive compound comprises an antiangiogenic agent and anti-platelet aggregation drug.

5 8. An absorbable stent coating as set forth in claim 1 wherein the at least one bioactive compound comprises paclitaxel and a non-steroidal anti-inflammatory drug.

9. An absorbable stent coating as set forth in claim 1 wherein the at least one bioactive compound comprises lanreotide and trapidil.

10 10. An absorbable stent coating as set forth in claim 9 wherein the lanreotide is at least partially conjugated ionically with the segmented/block copolymer.

11. An absorbable stent coating as set forth in claim 1 wherein the at least one bioactive compound comprises an ionic conjugate of a basic antiangiogenic peptide and an
15 acidic non-steroidal anti-inflammatory drug.

12. An absorbable stent coating as set forth in claim 11 wherein the acidic non-steroidal anti-inflammatory drug comprises naproxen.

20 13. An absorbable stent coating as set forth in claim 12 wherein the basic antiangiogenic peptide comprises an LHRH analog.

14. An absorbable stent coating as set forth in claim 12 wherein the basic antiangiogenic peptide comprises a somatostatin analog.

25

15. An absorbable stent coating as set forth in claim 1 wherein the at least one bioactive compound comprises an antiangiogenic peptide and an anti-platelet aggregation agent and wherein the antiangiogenic peptide and the anti-platelet aggregation agent are ionically conjugated with the segmented/block copolymer.

30

16. An absorbable stent coating as in set forth in claim 15 wherein the antiangiogenic peptide comprises lanreotide and the anti-platelet aggregation agent comprises trapidil.

5 17. A metallic endovascular stent coated with the absorbable stent coating of claim 1.

18. An absorbable endovascular stent coated with the absorbable stent coating of claim 1.

10

INTERNATIONAL SEARCH REPORT

Internat application No

PCT/US 03/12831

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61L31/10 A61L31/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 21908 A (ANGIOTECH PHARM INC ; UNIV BRITISH COLUMBIA (CA); BURT HELEN M (CA)) 6 May 1999 (1999-05-06)	1, 4-18
Y	page 8, line 20-26 page 13, line 22-28 page 15, line 15,16 page 21, line 11-19 page 22, line 3-16 page 27, line 17-25 page 28, line 22-27 page 30, line 20,21 example 1 page 46, line 30 claims 1,9,11	1-18

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

22 August 2003

Date of mailing of the international search report

02/09/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Böhm, I

INTERNATIONAL SEARCH REPORT

Internati Application No

PCT/US 03/12831

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 952 171 A (POLY MED INC) 27 October 1999 (1999-10-27) page 2, line 10 page 5, line 43-47 page 7, line 25 -page 8, line 29 page 9, line 52,53,55 page 13, line 4 ---	1-18
X	EP 0 737 703 A (POLY MED INC) 16 October 1996 (1996-10-16) claims 1,3,10,16,28,29; example 1 ---	1,4-16
A	US 5 073 381 A (IVAN BELA ET AL) 17 December 1991 (1991-12-17) column 1, line 12-30,49-56 column 8, line 24,26,31 column 9, line 29-39 ---	1-18
A	US 2001/032014 A1 (STANSLASKI JOEL L ET AL) 18 October 2001 (2001-10-18) page 1, paragraphs 1,6,9,10 column 2, paragraphs 20,21,23 column 3, paragraphs 25-27,31 ---	1,4-18
A	WO 01 01890 A (SCIMED LIFE SYSTEMS INC) 11 January 2001 (2001-01-11) claims ---	1,4-18
A	US 5 993 972 A (KUZMA JIRINA ET AL) 30 November 1999 (1999-11-30) column 3, line 15-42 column 3, line 66 -column 4, line 16 column 7, line 59-67 example 1 ---	1,4-18
A	JARR EM ET AL: "Sustained release of lidocaine from an injectable implant system for treatment of post-operative pain" PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM ON CONTROLLED RELEASE BIOACTIVE MATERIALS, XX, XX, vol. 26, July 1999 (1999-07), pages 631-632, XP002133945 ISSN: 1022-0178 example ---	1
A	US 6 210 717 B1 (KIM JIN SEOK ET AL) 3 April 2001 (2001-04-03) claims 1-4,21,42-45 ---	1

-/--

INTERNATIONAL SEARCH REPORT

Internatl pplication No
PCT/US 03/12831

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A,P	WO 02 055122 A (LEPPARD SIMON WILLIAM ;BIOCOMPATIBLES LTD (GB); LEWIS ANDREW LENNA) 18 July 2002 (2002-07-18) page 6, line 10-19 page 7, line 27 -page 8, line 12 claim 1	1,4-18
A,P	--- US 2002/164365 A1 (SHALABY SHALABY W ET AL) 7 November 2002 (2002-11-07) the whole document -----	1

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US 03/12831

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9921908	A	06-05-1999	US 2002164374 A1 AU 9617698 A CA 2348922 A1 WO 9921908 A1	07-11-2002 17-05-1999 06-05-1999 06-05-1999
EP 0952171	A	27-10-1999	US 6413539 B1 EP 0952171 A2 JP 3131195 B2 JP 2000026582 A US 2002164365 A1	02-07-2002 27-10-1999 31-01-2001 25-01-2000 07-11-2002
EP 0737703	A	16-10-1996	US 5612052 A AT 243720 T AU 685357 B2 AU 5056196 A CA 2174072 A1 DE 69628783 D1 DE 737703 T1 EP 0737703 A2 JP 3107514 B2 JP 9100343 A US 2002164365 A1 US 5714159 A	18-03-1997 15-07-2003 15-01-1998 31-10-1996 14-10-1996 31-07-2003 15-05-1997 16-10-1996 13-11-2000 15-04-1997 07-11-2002 03-02-1998
US 5073381	A	17-12-1991	US 4942204 A	17-07-1990
US 2001032014	A1	18-10-2001	US 6258121 B1 AU 5790500 A CA 2342866 A1 EP 1107707 A1 JP 2003503153 T WO 0101890 A1	10-07-2001 22-01-2001 11-01-2001 20-06-2001 28-01-2003 11-01-2001
WO 0101890	A	11-01-2001	US 6258121 B1 AU 5790500 A CA 2342866 A1 EP 1107707 A1 JP 2003503153 T WO 0101890 A1 US 2001032014 A1	10-07-2001 22-01-2001 11-01-2001 20-06-2001 28-01-2003 11-01-2001 18-10-2001
US 5993972	A	30-11-1999	US 5962620 A AU 3090499 A WO 9947127 A1 EP 0920467 A1 WO 9808884 A1	05-10-1999 11-10-1999 23-09-1999 09-06-1999 05-03-1998
US 6210717	B1	03-04-2001	US 6410057 B1 AU 740342 B2 AU 1910899 A BR 9813548 A CN 1281355 T EP 1037611 A1 JP 2001525357 T KR 2001032878 A WO 9929303 A1 ZA 9811376 A	25-06-2002 01-11-2001 28-06-1999 10-10-2000 24-01-2001 27-09-2000 11-12-2001 25-04-2001 17-06-1999 28-06-1999

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat pplication No

PCT/US 03/12831

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 02055122	A	18-07-2002	WO 02055122 A1	18-07-2002
US 2002164365	A1	07-11-2002	US 6413539 B1	02-07-2002
			US 5714159 A	03-02-1998
			US 5612052 A	18-03-1997
			EP 0952171 A2	27-10-1999
			JP 3131195 B2	31-01-2001
			JP 2000026582 A	25-01-2000
			AT 243720 T	15-07-2003
			AU 685357 B2	15-01-1998
			AU 5056196 A	31-10-1996
			CA 2174072 A1	14-10-1996
			DE 69628783 D1	31-07-2003
			DE 737703 T1	15-05-1997
			EP 0737703 A2	16-10-1996
			JP 3107514 B2	13-11-2000
			JP 9100343 A	15-04-1997